share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3：特定交易注册声明
美股SEC公告 ·  09/19 16:36

Moomoo AI 已提取核心信息

60 Degrees Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on September 19, 2024, for the resale of up to 8,913,044 shares of common stock. These shares are related to certain Pre-Funded Warrants, Series A Warrants, Series B Warrants, and Placement Agent Warrants issued in connection with a private placement completed on September 5, 2024. The selling stockholders may sell these shares on the Nasdaq Capital Market or in private transactions at fixed or varying prices. The company will not receive any proceeds from the sale of these shares by the selling stockholders. The registration statement includes the company's financial statements for the years ended December 31, 2023, and 2022, and incorporates by reference additional documents filed with the SEC. 60 Degrees Pharmaceuticals is subject to Section 203 of the Delaware General Corporation Law, which may affect future corporate takeovers. The company's common stock and warrants are listed on The Nasdaq Capital Market under the symbols 'SXTP' and 'SXTPW' respectively.
60 Degrees Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on September 19, 2024, for the resale of up to 8,913,044 shares of common stock. These shares are related to certain Pre-Funded Warrants, Series A Warrants, Series B Warrants, and Placement Agent Warrants issued in connection with a private placement completed on September 5, 2024. The selling stockholders may sell these shares on the Nasdaq Capital Market or in private transactions at fixed or varying prices. The company will not receive any proceeds from the sale of these shares by the selling stockholders. The registration statement includes the company's financial statements for the years ended December 31, 2023, and 2022, and incorporates by reference additional documents filed with the SEC. 60 Degrees Pharmaceuticals is subject to Section 203 of the Delaware General Corporation Law, which may affect future corporate takeovers. The company's common stock and warrants are listed on The Nasdaq Capital Market under the symbols 'SXTP' and 'SXTPW' respectively.
60 Degrees Pharmaceuticals, Inc.于2024年9月19日向美国证券交易委员会（SEC）提交了注册声明，用于转售最多8,913,044股普通股。这些股份与于2024年9月5日完成的定向增发交易相关的某些预先筹资认股权、A系列认股权、B系列认股权和放置代理认股权有关。出售股票的股东可以在纳斯达克资本市场或以固定或变动价格进行私人交易出售这些股票。公司不会获得出售股票的股东的任何收益。注册声明包括公司截至2023年12月31日和2022年的财务报表，并引用了与SEC提交的其他文件。60 Degrees Pharmaceuticals受特拉华州普通公司法第203条的管辖，该法可能影响未来的企业收购。该公司的普通股和认股权分别在纳斯达克资本市场上市，交易代码分别为'SXTP'和'SXTPW'。
60 Degrees Pharmaceuticals, Inc.于2024年9月19日向美国证券交易委员会（SEC）提交了注册声明，用于转售最多8,913,044股普通股。这些股份与于2024年9月5日完成的定向增发交易相关的某些预先筹资认股权、A系列认股权、B系列认股权和放置代理认股权有关。出售股票的股东可以在纳斯达克资本市场或以固定或变动价格进行私人交易出售这些股票。公司不会获得出售股票的股东的任何收益。注册声明包括公司截至2023年12月31日和2022年的财务报表，并引用了与SEC提交的其他文件。60 Degrees Pharmaceuticals受特拉华州普通公司法第203条的管辖，该法可能影响未来的企业收购。该公司的普通股和认股权分别在纳斯达克资本市场上市，交易代码分别为'SXTP'和'SXTPW'。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间